Global Human Rabies Immunoglobulin (IM) Market Size, Manufacturers, Opportunities and Forecast to 2030
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
According to APO Research, The global Human Rabies Immunoglobulin (IM) market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
According to APO Research, The global Human Rabies Immunoglobulin (IM) market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- CSL Behring
- Grifols
- Sanofi
- Sichuan Yuanda Shuyang
- CNBG
- Kamada
- CBPO
- Shuanglin Bio
- Weiguang Bio
- Shanghai RAAS
- Bharat Serum
- VINS
- ERIG
- HRIG
- Category II Exposure
- Category III Exposure
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Human Rabies Immunoglobulin (IM) Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Human Rabies Immunoglobulin (IM) Sales Estimates and Forecasts (2019-2030)
1.3 Human Rabies Immunoglobulin (IM) Market by Type
1.3.1 ERIG
1.3.2 HRIG
1.4 Global Human Rabies Immunoglobulin (IM) Market Size by Type
1.4.1 Global Human Rabies Immunoglobulin (IM) Market Size Overview by Type (2019-2030)
1.4.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size Review by Type (2019-2024)
1.4.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Type (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.4 Latin America Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.5 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Human Rabies Immunoglobulin (IM) Industry Trends
2.2 Human Rabies Immunoglobulin (IM) Industry Drivers
2.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
2.4 Human Rabies Immunoglobulin (IM) Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Human Rabies Immunoglobulin (IM) Revenue (2019-2024)
3.2 Global Top Players by Human Rabies Immunoglobulin (IM) Sales (2019-2024)
3.3 Global Top Players by Human Rabies Immunoglobulin (IM) Price (2019-2024)
3.4 Global Human Rabies Immunoglobulin (IM) Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Human Rabies Immunoglobulin (IM) Key Company Manufacturing Sites & Headquarters
3.6 Global Human Rabies Immunoglobulin (IM) Company, Product Type & Application
3.7 Global Human Rabies Immunoglobulin (IM) Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Human Rabies Immunoglobulin (IM) Market CR5 and HHI
3.8.2 Global Top 5 and 10 Human Rabies Immunoglobulin (IM) Players Market Share by Revenue in 2023
3.8.3 2023 Human Rabies Immunoglobulin (IM) Tier 1, Tier 2, and Tier
4 HUMAN RABIES IMMUNOGLOBULIN (IM) REGIONAL STATUS AND OUTLOOK
4.1 Global Human Rabies Immunoglobulin (IM) Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size by Region
4.2.1 Global Human Rabies Immunoglobulin (IM) Sales in Volume by Region (2019-2024)
4.2.2 Global Human Rabies Immunoglobulin (IM) Sales in Value by Region (2019-2024)
4.2.3 Global Human Rabies Immunoglobulin (IM) Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Region
4.3.1 Global Human Rabies Immunoglobulin (IM) Sales in Volume by Region (2025-2030)
4.3.2 Global Human Rabies Immunoglobulin (IM) Sales in Value by Region (2025-2030)
4.3.3 Global Human Rabies Immunoglobulin (IM) Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 HUMAN RABIES IMMUNOGLOBULIN (IM) BY APPLICATION
5.1 Human Rabies Immunoglobulin (IM) Market by Application
5.1.1 Category II Exposure
5.1.2 Category III Exposure
5.2 Global Human Rabies Immunoglobulin (IM) Market Size by Application
5.2.1 Global Human Rabies Immunoglobulin (IM) Market Size Overview by Application (2019-2030)
5.2.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size Review by Application (2019-2024)
5.2.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 CSL Behring
6.1.1 CSL Behring Comapny Information
6.1.2 CSL Behring Business Overview
6.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
6.1.5 CSL Behring Recent Developments
6.2 Grifols
6.2.1 Grifols Comapny Information
6.2.2 Grifols Business Overview
6.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
6.2.5 Grifols Recent Developments
6.3 Sanofi
6.3.1 Sanofi Comapny Information
6.3.2 Sanofi Business Overview
6.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
6.3.5 Sanofi Recent Developments
6.4 Sichuan Yuanda Shuyang
6.4.1 Sichuan Yuanda Shuyang Comapny Information
6.4.2 Sichuan Yuanda Shuyang Business Overview
6.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
6.4.5 Sichuan Yuanda Shuyang Recent Developments
6.5 CNBG
6.5.1 CNBG Comapny Information
6.5.2 CNBG Business Overview
6.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
6.5.5 CNBG Recent Developments
6.6 Kamada
6.6.1 Kamada Comapny Information
6.6.2 Kamada Business Overview
6.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
6.6.5 Kamada Recent Developments
6.7 CBPO
6.7.1 CBPO Comapny Information
6.7.2 CBPO Business Overview
6.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
6.7.5 CBPO Recent Developments
6.8 Shuanglin Bio
6.8.1 Shuanglin Bio Comapny Information
6.8.2 Shuanglin Bio Business Overview
6.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.8.5 Shuanglin Bio Recent Developments
6.9 Weiguang Bio
6.9.1 Weiguang Bio Comapny Information
6.9.2 Weiguang Bio Business Overview
6.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.9.5 Weiguang Bio Recent Developments
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Comapny Information
6.10.2 Shanghai RAAS Business Overview
6.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
6.10.5 Shanghai RAAS Recent Developments
6.11 Bharat Serum
6.11.1 Bharat Serum Comapny Information
6.11.2 Bharat Serum Business Overview
6.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
6.11.5 Bharat Serum Recent Developments
6.12 VINS
6.12.1 VINS Comapny Information
6.12.2 VINS Business Overview
6.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
6.12.5 VINS Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Human Rabies Immunoglobulin (IM) Sales by Country
7.1.1 North America Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
7.1.3 North America Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
7.2 North America Human Rabies Immunoglobulin (IM) Market Size by Country
7.2.1 North America Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
7.2.3 North America Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Human Rabies Immunoglobulin (IM) Sales by Country
8.1.1 Europe Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
8.1.3 Europe Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
8.2 Europe Human Rabies Immunoglobulin (IM) Market Size by Country
8.2.1 Europe Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
8.2.3 Europe Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales by Country
9.1.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
9.1.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size by Country
9.2.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Human Rabies Immunoglobulin (IM) Sales by Country
10.1.1 Latin America Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
10.1.3 Latin America Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
10.2 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country
10.2.1 Latin America Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
10.2.3 Latin America Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country
11.1.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
11.1.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country
11.2.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
12.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Human Rabies Immunoglobulin (IM) Production Mode & Process
12.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Human Rabies Immunoglobulin (IM) Distributors
12.2.3 Human Rabies Immunoglobulin (IM) Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Human Rabies Immunoglobulin (IM) Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Human Rabies Immunoglobulin (IM) Sales Estimates and Forecasts (2019-2030)
1.3 Human Rabies Immunoglobulin (IM) Market by Type
1.3.1 ERIG
1.3.2 HRIG
1.4 Global Human Rabies Immunoglobulin (IM) Market Size by Type
1.4.1 Global Human Rabies Immunoglobulin (IM) Market Size Overview by Type (2019-2030)
1.4.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size Review by Type (2019-2024)
1.4.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Type (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.4 Latin America Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
1.5.5 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Human Rabies Immunoglobulin (IM) Industry Trends
2.2 Human Rabies Immunoglobulin (IM) Industry Drivers
2.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
2.4 Human Rabies Immunoglobulin (IM) Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Human Rabies Immunoglobulin (IM) Revenue (2019-2024)
3.2 Global Top Players by Human Rabies Immunoglobulin (IM) Sales (2019-2024)
3.3 Global Top Players by Human Rabies Immunoglobulin (IM) Price (2019-2024)
3.4 Global Human Rabies Immunoglobulin (IM) Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Human Rabies Immunoglobulin (IM) Key Company Manufacturing Sites & Headquarters
3.6 Global Human Rabies Immunoglobulin (IM) Company, Product Type & Application
3.7 Global Human Rabies Immunoglobulin (IM) Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Human Rabies Immunoglobulin (IM) Market CR5 and HHI
3.8.2 Global Top 5 and 10 Human Rabies Immunoglobulin (IM) Players Market Share by Revenue in 2023
3.8.3 2023 Human Rabies Immunoglobulin (IM) Tier 1, Tier 2, and Tier
4 HUMAN RABIES IMMUNOGLOBULIN (IM) REGIONAL STATUS AND OUTLOOK
4.1 Global Human Rabies Immunoglobulin (IM) Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size by Region
4.2.1 Global Human Rabies Immunoglobulin (IM) Sales in Volume by Region (2019-2024)
4.2.2 Global Human Rabies Immunoglobulin (IM) Sales in Value by Region (2019-2024)
4.2.3 Global Human Rabies Immunoglobulin (IM) Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Region
4.3.1 Global Human Rabies Immunoglobulin (IM) Sales in Volume by Region (2025-2030)
4.3.2 Global Human Rabies Immunoglobulin (IM) Sales in Value by Region (2025-2030)
4.3.3 Global Human Rabies Immunoglobulin (IM) Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 HUMAN RABIES IMMUNOGLOBULIN (IM) BY APPLICATION
5.1 Human Rabies Immunoglobulin (IM) Market by Application
5.1.1 Category II Exposure
5.1.2 Category III Exposure
5.2 Global Human Rabies Immunoglobulin (IM) Market Size by Application
5.2.1 Global Human Rabies Immunoglobulin (IM) Market Size Overview by Application (2019-2030)
5.2.2 Global Human Rabies Immunoglobulin (IM) Historic Market Size Review by Application (2019-2024)
5.2.3 Global Human Rabies Immunoglobulin (IM) Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 CSL Behring
6.1.1 CSL Behring Comapny Information
6.1.2 CSL Behring Business Overview
6.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
6.1.5 CSL Behring Recent Developments
6.2 Grifols
6.2.1 Grifols Comapny Information
6.2.2 Grifols Business Overview
6.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
6.2.5 Grifols Recent Developments
6.3 Sanofi
6.3.1 Sanofi Comapny Information
6.3.2 Sanofi Business Overview
6.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
6.3.5 Sanofi Recent Developments
6.4 Sichuan Yuanda Shuyang
6.4.1 Sichuan Yuanda Shuyang Comapny Information
6.4.2 Sichuan Yuanda Shuyang Business Overview
6.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
6.4.5 Sichuan Yuanda Shuyang Recent Developments
6.5 CNBG
6.5.1 CNBG Comapny Information
6.5.2 CNBG Business Overview
6.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
6.5.5 CNBG Recent Developments
6.6 Kamada
6.6.1 Kamada Comapny Information
6.6.2 Kamada Business Overview
6.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
6.6.5 Kamada Recent Developments
6.7 CBPO
6.7.1 CBPO Comapny Information
6.7.2 CBPO Business Overview
6.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
6.7.5 CBPO Recent Developments
6.8 Shuanglin Bio
6.8.1 Shuanglin Bio Comapny Information
6.8.2 Shuanglin Bio Business Overview
6.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.8.5 Shuanglin Bio Recent Developments
6.9 Weiguang Bio
6.9.1 Weiguang Bio Comapny Information
6.9.2 Weiguang Bio Business Overview
6.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.9.5 Weiguang Bio Recent Developments
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Comapny Information
6.10.2 Shanghai RAAS Business Overview
6.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
6.10.5 Shanghai RAAS Recent Developments
6.11 Bharat Serum
6.11.1 Bharat Serum Comapny Information
6.11.2 Bharat Serum Business Overview
6.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
6.11.5 Bharat Serum Recent Developments
6.12 VINS
6.12.1 VINS Comapny Information
6.12.2 VINS Business Overview
6.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
6.12.5 VINS Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Human Rabies Immunoglobulin (IM) Sales by Country
7.1.1 North America Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
7.1.3 North America Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
7.2 North America Human Rabies Immunoglobulin (IM) Market Size by Country
7.2.1 North America Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
7.2.3 North America Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Human Rabies Immunoglobulin (IM) Sales by Country
8.1.1 Europe Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
8.1.3 Europe Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
8.2 Europe Human Rabies Immunoglobulin (IM) Market Size by Country
8.2.1 Europe Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
8.2.3 Europe Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales by Country
9.1.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
9.1.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size by Country
9.2.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Human Rabies Immunoglobulin (IM) Sales by Country
10.1.1 Latin America Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
10.1.3 Latin America Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
10.2 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country
10.2.1 Latin America Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
10.2.3 Latin America Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country
11.1.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2019-2024)
11.1.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country
11.2.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
12.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Human Rabies Immunoglobulin (IM) Production Mode & Process
12.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Human Rabies Immunoglobulin (IM) Distributors
12.2.3 Human Rabies Immunoglobulin (IM) Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
